Japanese biotechnology company specializing in AI-driven discovery of mRNA-targeted small molecule and nucleic acid drugs using its aibVIS platform. Engaged in joint research and patent filings with pharmaceutical partners for lncRNA-targeting therapies. Listed on Tokyo Stock Exchange Growth Market.
Patent application covers a nucleic acid therapeutic against lncRNA H19 developed with an AI-driven discovery platform; commercialization planned using dedicated CRDMO capacity.
